What is the Global market size of the Central Nervous System Treatment Market?

Global Central Nervous System Treatment Market size was valued at USD 120.64 billion in 2021 and is poised to grow from USD 128.29 billion in 2022 to USD 209.2 billion by 2030, growing at a CAGR of 6.3% in the forecast period (2023-2030).

Top Central Nervous System Treatment Companies

Skyquest Technology's expert advisors have carried out comprehensive research and identified these companies as industry leaders in the Central Nervous System Treatment Market. This Analysis is based on comprehensive primary and secondary research on the corporate strategies, financial and operational performance, product portfolio, market share and brand analysis of all the leading Central Nervous System Treatment industry players.

Central Nervous System Treatment Market Competitive Landscape

Central Nervous System Treatment Market Top Players Company Profiles

Pfizer Inc.
Novartis International AG
Johnson & Johnson
GlaxoSmithKline plc
Merck & Co., Inc.
AbbVie Inc.
Sanofi S.A.
Eli Lilly and Company
AstraZeneca plc
Biogen Inc.
Teva Pharmaceutical Industries Ltd.
UCB S.A.
Boehringer Ingelheim International GmbH
Bristol-Myers Squibb Company
Ipsen S.A.
Lundbeck A/S
Otsuka Holdings Co., Ltd.
Sunovion Pharmaceuticals Inc.
Takeda Pharmaceutical Company Limited
Vertex Pharmaceuticals Incorporated

REPORT OVERVIEW BUY NOW

REQUEST FOR SAMPLE

Want to customize this report?

REQUEST FREE CUSTOMIZATION

FAQs

Global Central Nervous System Treatment Market size was valued at USD 144.96 Billion in 2024 and is poised to grow from USD 154.09 Billion in 2025 to USD 251.22 Billion by 2033, growing at a CAGR of 6.3% during the forecast period (2026–2033).

Mergers, acquisitions, and partnerships are among the important market trends that are present. Major players in the market who are developing novel therapeutics for the treatment of disorders of the central nervous system have agreements with rival firms for distribution and research and development. For instance, Biogen and Sangamo Therapeutics reached an agreement to develop novel gene therapy medications for a range of neurological illnesses. The prospects of the CNS therapeutics market would be greatly improved by strategic actions implemented by leading businesses. 'Johnson & Johnson', 'Bristol Myers Squibb', 'Otsuka Pharmaceutical Co., Ltd.', 'Eli Lilly', 'Biogen', 'Genentech/Eisai', 'Roche', 'Neurocrine Biosciences', 'Novartis', 'Pfizer', 'Sanofi', 'Merck & Co.', 'GSK', 'AstraZeneca', 'Teva Pharmaceuticals', 'H. Lundbeck', 'Acorda Therapeutics', 'Alzheon', 'Delix Therapeutics', 'Cerevel Therapeutics'

The frequency and incidence of neurological illnesses, including multiple sclerosis, Alzheimer's disease, and Parkinson's disease, among others, are rapidly rising globally. In the upcoming years, the market's growth is expected to be significantly impacted by this increase. On the other side, countries with an increasing geriatric population are also experiencing an upsurge in the prevalence of Alzheimer's disease. For instance, the Alzheimer's Association estimates that more than five million people worldwide already suffer from Alzheimer's disease, and that figure is expected to increase to 14 million by the year 2050.

Improvements in Diagnosis and Therapeutics: The development of the therapeutics market for the central nervous system is being fuelled by improvements in diagnostics, therapies, and drug discovery approaches.

By holding the greatest revenue share of 49.3%, North America dominated the market for CNS therapeutics. The presence of large corporations and efforts made by major medical organizations to create novel medicines for various central nervous system ailments are the factors anticipated to enhance the total market share.

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

Click here

Feedback From Our Clients

"We have purchased recently a report from SkyQuest Technology, and we are happy to inform you that this report was so useful and practical for our team. Skyquest Team was very active and our queries were followed up completely.It was amazing. "

- Mr. Luca Giovannini, Marketing Innovation Senior Manager, Trelleborg.

Central Nervous System Treatment Market

Report ID: SQMIG35B2179

sales@skyquestt.com
USA +1 351-333-4748

BUY NOW GET FREE SAMPLE

Top Central Nervous System Treatment Companies

Central Nervous System Treatment Market Competitive Landscape

FAQs

What is the global market size of Central Nervous System Treatment Market?

Who are the key vendors in the Central Nervous System Treatment Market?

What is the key driver of Central Nervous System Treatment Market?

What is the key market trend for Central Nervous System Treatment Market?

Which region accounted for the largest share in Central Nervous System Treatment Market?

Request Free Customization